Not sure how
"Planning further in
vivo tests with
scaffolds targeting
intracellular targets" can be past tense, but i guess we both know how they have played with words in the past. My thought was dr Hayes is giving them a free spin, as if planning tests should be part of a deal but maybe its just a taster to show them how things have progressed since original trial. Hard to believe after his involvement with Janssens that he wouldnt want to try and use any contacts he has to resurect the original deal if we really have progressed as far as claimed.
Interresting to see slide 11 shows 75% validation on breast cancer and 25% on leukemia. I thought we had specialised in blood cancer. That is one thing that doesnt change, ie the goalposts are on the back of a ute they move so often.
PYC Price at posting:
4.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)